LEO Pharma

We have Sid Prabhu, Senior Director, Head of Found Data at Novo Nordisk.

And we have Parag Naithani, Head of Statistical Programming at Leo Pharma.

And today we're here to discuss how we can remain innovative in a heavily regulated environment such as pharmaceutical, right? And before we delve any deeper into the topic, let's work our way around the room with some introductions.

So I'd like to know who you are, what you do and what your biggest passion is currently.

I need that tool without really understanding that, you know, they already have a lot and they can actually do almost everything they want to do with the current, uh, you know, infrastructure that they have.

So again, Coming to experimentation, right? Like we cannot stop or we shouldn't be stopping people from experimenting.

But I do feel that AI is going to be implemented at least at Leo Pharma.

We have the strategy.

So my name is Lucas Iagina.

I work for Leo Pharma.

here in the US.

I oversee our rare disease team that we've been building now at Leo for over a year.

And so what we were able to show the company that was running the study was that patients using this potential treatment were able to stay significantly longer outside in the sunlight before experiencing those first symptoms.

And as I said, we're working right now on the publication and looking forward to being able to publish it in one of the journals in the near future.

Can you talk about Leo Pharma's commitment to rare dermatology and rare skin diseases?

Where do I start? I mean, look, I think the key thing that, and I mentioned this at the beginning, first of all, Leo Pharma is not a new game in town.